CurrentMedical Mutual - OhioPolicy N/A

Kisqali (ribociclib) and Kisqali Femara Co-Pack coverage

Defines prior authorization, clinical coverage criteria, and approval durations for Kisqali (ribociclib) alone or as a co-pack with letrozole for treating HR+, HER2- advanced or high-risk early breast cancer in adults; applies to Medical Mutual - Ohio pharmacy benefit reviews.

Policy Summary

PayerMedical Mutual - Ohio

PolicyKisqali (ribociclib) and Kisqali Femara Co-Pack coverage

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateN/A

Next Review DateFeb 19, 2026

Key ActionObtain prior authorization and ensure initial prescribing is by or in consultation with a hematologist or oncologist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsInitial approval duration

1 yearExtended approval duration

HR+, HER2-Target tumor biomarker profile

Oncology requiredSpecialist prescriber

Men & pre/postmenopausal womenCovered populations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Medical necessity criteria

Coverage is recommended when ALL of the following criteria are met for the specified populations:

Core eligibility: Patient has recurrent, advanced, or metastatic disease, or early disease (stage II or III) at high risk of recurrence; AND patient has hormone receptor–positive (ER+ and/or PR+) disease; AND patient has HER2‑negative breast cancer

High risk of recurrence includes any lymph node involvement; tumor size > 5 cm; or tumor size 2–5 cm with either grade 2 (and high genomic risk or Ki‑67 ≥ 20%) or grade 3 disease.

Women: population- and therapy-specific options: For women, ONE of: (i) postmenopausal and Kisqali used as first-line endocrine therapy in combination with anastrozole, exemestane, letrozole, OR fulvestrant; OR (ii) postmenopausal and Kisqali Femara Co‑Pack used as first-line endocrine therapy; OR (iii) postmenopausal and Kisqali used as second‑line or subsequent endocrine therapy in combination with fulvestrant only if a CDK4/6 inhibitor has not been used previously; OR (iv) premenopausal or perimenopausal with ovarian suppression/ablation (GnRH agonist, bilateral oophorectomy, or ovarian irradiation) AND one of the options: first‑line with an AI or fulvestrant, Kisqali Femara Co‑Pack first‑line, or second‑line with fulvestrant if no prior CDK4/6 inhibitor

Premenopausal/perimenopausal patients must receive ovarian suppression/ablation (examples: leuprolide, triptorelin, goserelin).

Men: population- and therapy-specific options: For men, ONE of: (i) Kisqali used as first‑line endocrine therapy in combination with anastrozole, exemestane, letrozole, OR fulvestrant; OR (ii) Kisqali Femara Co‑Pack used as first‑line endocrine therapy; OR (iii) Kisqali used as second‑line or subsequent endocrine therapy in combination with fulvestrant only if a CDK4/6 inhibitor has not been used previously

Men receiving an aromatase inhibitor must receive concomitant GnRH agonist for testicular suppression (examples: leuprolide, triptorelin, goserelin).

Other guideline-supported indications: Any other indication cited in the NCCN guidelines as category 1, 2A, or 2B may be approved

Prescriber must provide specific diagnosis documentation.

Continuation of therapy: Approve continuation if prescriber provides evidence of beneficial response warranting continuation of therapy

Initial approval duration: 6 months; extended approval duration: 1 year.

Uses not listed in this policy will be reviewed on a case-by-case basis and require submission of supporting evidence for efficacy and medical necessity. Such requests may be considered investigational or not recommended for approval unless the reviewer determines there is sufficient clinical evidence and documented need to support coverage.

Therapy may be denied if the drug or service is determined to be investigational/experimental or not medically necessary following review. The Company may also deny reimbursement if the treatment is not within the member’s scope of benefits or if inappropriate or excessive billing or practice patterns are identified. The Company reserves the right to modify, revise, change, apply, and interpret this policy at its sole discretion.

Regimen	Indication / line of therapy	Coverage status
Ribociclib in combination with anastrozole
HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression)

Ribociclib in combination with exemestane
HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression)

Ribociclib in combination with letrozole
HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression)

Ribociclib in combination with fulvestrant
HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy or second‑line/subsequent therapy with fulvestrant only if no prior CDK4/6 inhibitor exposure (postmenopausal or premenopausal with ovarian suppression)

Kisqali Femara Co‑Pack (ribociclib + letrozole)
HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression)

Prior Authorization Codes and Biomarker Thresholds

Prior authorization affected codesmixed

affected codes

placeholder for pharmacy benefit codes referenced by payer

Ki-67 — numeric biomarker threshold

Ki-67 threshold>= 20%

Use in defining high genomic riskKi-67 ≥ 20% qualifies tumor 2-5 cm with grade 2 as high genomic risk

Context of applicationApplied when determining high risk of recurrence for early-stage (stage II/III) disease

Prior Authorization, Prescriber Requirements, and Documentation

Prior Authorization

Prior Authorization Recommended

Prior authorization is recommended for pharmacy benefit coverage of Kisqali/Kisqali Femara Co-Pack. Initial prescribing must be by or in consultation with a physician who specializes in the condition being treated; specifically, the drug must be prescribed by or in consultation with a hematologist or oncologist for initial therapy. All approvals for initial therapy are provided for the initial approval duration noted in the policy.

Prior authorization recommended for pharmacy benefit
Initial prescriber: hematologist or oncologist (or in consultation with one)
Initial approvals provided for the initial approval duration specified in the policy

Step Therapy

Line of Therapy Constraints

Line of therapy constraints apply based on prior exposure to CDK4/6 inhibitors and menopausal status. For postmenopausal patients, Kisqali may be used as first-line endocrine therapy in combination with anastrozole, exemestane, letrozole, or fulvestrant, or as first-line when using the Kisqali Femara Co-Pack. Kisqali may be used as second-line or subsequent endocrine therapy in combination with fulvestrant only if a CDK4/6 inhibitor has not been used previously. For premenopausal or perimenopausal patients receiving ovarian suppression/ablation, the same first-line and restricted second-line rules apply. Equivalent line-of-therapy rules apply for men meeting criteria, with concomitant GnRH agonist when combined with an aromatase inhibitor.

Definitions and Risk Stratification

High risk of recurrence — definition

Any lymph node involvementPresence of any lymph node metastasis qualifies as high risk of recurrence

Tumor size > 5 cmPrimary tumor size greater than 5 cm qualifies as high risk

Tumor size 2–5 cm with grade criteriaTumor 2–5 cm with either grade 2 (and high genomic risk or Ki-67 ≥ 20%) or grade 3 disease qualifies as high risk

Line of Therapy Criteria

Line of therapy — first-line | second-line

Line of therapy options: First‑line endocrine therapy in combination with an aromatase inhibitor (anastrozole, exemestane, letrozole) or fulvestrant; OR second‑line/subsequent endocrine therapy in combination with fulvestrant only if a CDK4/6 inhibitor has not been used previously

Different rules apply by patient group: premenopausal/perimenopausal patients require ovarian suppression/ablation; men require concomitant GnRH agonist when receiving an aromatase inhibitor.

Hormone Receptor and HER2 Status; Proliferation Index

HR (ER/PR) and HER2 — biomarker requirements

Hormone receptor status requiredHR+ defined as estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)

HER2 status requiredHER2-negative disease required

Combined biomarker requirementPatient must have HR+ (ER+ and/or PR+) AND HER2-negative breast cancer

Ki-67 — proliferation index threshold

Proliferation index threshold>= 20% Ki-67 defines high proliferation (used to identify high genomic risk)

Role in early diseaseKi-67 ≥ 20% applied to tumors 2–5 cm with grade 2 to qualify as high risk of recurrence

Clinical Background

Ribociclib is a cyclin-dependent kinase (CDK4/6) inhibitor that prevents phosphorylation of the retinoblastoma protein (Rb), producing G1 cell-cycle arrest and decreased cellular proliferation in estrogen receptor–positive (ER+) breast cancer. It is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for appropriate patients and is available as single-agent tablets or co‑packaged with letrozole.

Policy Revision History

2026-02-19policy_review_and_revisionLatest

Annual review completed; policy last revised and reviewed on 02/19/2026.

initial_approval_settings

Initial and extended approval durations defined (initial 6 months; extended 1 year).